Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 5, 2011, Pages 718-725

  Madlensky, L ^a   Natarajan, L ^a   Tchu, S ^b   Pu, M ^a   Mortimer, J ^c   Flatt, S W ^a   Nikoloff, D M ^d   Hillman, G ^d   Fontecha, M R ^d   Lawrence, H J ^d   Parker, B A ^a   Wu, A H B ^b   Pierce, J P ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY TAMOXIFEN; CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN; ESTROGEN RECEPTOR; NORTAMOXIFEN; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; COHORT ANALYSIS; CYP2D6 GENE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME;

BREAST NEOPLASMS; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PHENOTYPE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79955485361     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.32     Document Type: Article

References (32)

1. Fisher, B. et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. 88, 1529-1542 (1996). (Pubitemid 26374506)
2. Jordan, V.C. Metabolites of tamoxifen in animals and man: identification, Pharmacology, And significance. Breast Cancer Res. Treat. 2, 123-138 (1982). (Pubitemid 13233530)
3. Lien, E.A., Solheim, E., Kvinnsland, S. & Ueland, P.M. Identification of 4-hydroxy- N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 48, 2304-2308 (1988).
4. Johnson, M.D. et al. Pharmacological characterization of 4-hydroxy-Ndesmethyl tamoxifen, A novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85, 151-159 (2004). (Pubitemid 38987269)
5. Lim, Y.C. et al. Endoxifen, A secondary metabolite of tamoxifen, And 4-OHtamoxifen induce similar changes in global gene expression patterns in MCF- 7 breast cancer cells. J. Pharmacol. Exp. Ther. 318, 503-512 (2006).
6. Borges, S. et al. Quantitative effect of CyP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61-74 (2006). (Pubitemid 43946844)
7. Jin, Y. et al. CyP2D6 genotype, Antidepressant use, And tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39 (2005).
8. Stearns, V. et al. active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764 (2003). (Pubitemid 38008898)
9. Ferraldeschi, R. & Newman, W.G. The impact of CyP2D6 genotyping on tamoxifen treatment. Pharmaceuticals 3, 1122-1138 (2010).
10. Lash, T.L. & Rosenberg, C.L. Evidence and practice regarding the role for CyP2D6 inhibition in decisions about tamoxifen therapy. J. Clin. Oncol. 28, 1273-1275 (2010).
11. Borges, S. et al. Composite functional genetic and comedication CyP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J. Clin. Pharmacol. 50, 450-458 (2010).
12. De Sloover Koch, Y. & Ernst, M.E. Selective serotonin-reuptake inhibitors for the treatment of hot flashes. Ann. Pharmacother. 38, 1293-1296 (2004). (Pubitemid 38802178)
13. Loprinzi, C.L. et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356, 2059-2063 (2000). (Pubitemid 32009821)
14. Pandya, K.J. et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann. Intern. Med. 132, 788-793 (2000). (Pubitemid 30317793)
15. Flockhart, D. CyP2D6 genotyping and the pharmacogenetics of tamoxifen. Clin. Adv. Hematol. Oncol. 6, 493-494 (2008).
16. Jeppesen, U., Gram, L.F., Vistisen, K., Loft, S., Poulsen, H.E. & Brøsen, K. Dosedependent inhibition of CyP1a2, CyP2C19 and CyP2D6 by citalopram, Fluoxetine, Fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 51, 73-78 (1996). (Pubitemid 26300937)
17. Mortimer, J.E. et al. Tamoxifen, Hot flashes and recurrence in breast cancer. Breast Cancer Res. Treat. 108, 421-426 (2008). (Pubitemid 351431079)
18. Pierce, J.P. et al. a randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Control. Clin. Trials 23, 728-756 (2002). (Pubitemid 36005481)
19. Pierce, J.P. et al. Influence of a diet very high in vegetables, Fruit, And fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298, 289-298 (2007). (Pubitemid 47080483)
20. Tableman, M. & Kim J.S. Survival Analysis Using S: Analysis of Time-to-Event Data (Chapman & Hall/CRC, Boca Raton, FL, 2004).
21. Schumacher, M., Hollander, N. & Sauerbrei, W. Resampling and crossvalidation techniques: a tool to reduce bias caused by model building? Stat. Med. 16, 2813-2827 (1997). (Pubitemid 27520634)
22. Wu, A.H. et al. Tamoxifen, Soy, And lifestyle factors in asian american women with breast cancer. J. Clin. Oncol. 25, 3024-3030 (2007). (Pubitemid 47218048)
23. Lash, T.L., Lien, E.A., Sørensen, H.T. & Hamilton-Dutoit, S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 10, 825-833 (2009).
24. Decensi, A. et al. a randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J. Natl. Cancer Inst. 95, 779-790 (2003). (Pubitemid 36798424)
25. Guerrieri-Gonzaga, A. et al. Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol. Biomarkers Prev. 10, 967-970 (2001). (Pubitemid 32844905)
26. Anderson, W.F., Chen, B.E., Jatoi, I. & Rosenberg, P.S. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res. Treat. 100, 121-126 (2006).
27. Dignam, J.J., Dukic, V., Anderson, S.J., Mamounas, E.P., Wickerham, D.L. & Wolmark, N. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res. Treat. 116, 595-602 (2009).
28. Hess, K.R., Pusztai, L., Buzdar, A.U. & Hortobagyi, G.N. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res. Treat. 78, 105-118 (2003). (Pubitemid 36223023)
29. Natarajan, L. et al. Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. Am. J. Epidemiol. 169, 1463-1470 (2009).
30. AJCC. American Joint Committee on Cancer: Manual for Staging of Cancer 6th edn. (ed. Fleming I.D.) (Springer, New york, 2002).
31. Thomson, G. et al. Testing fit of genotype frequencies to Hardy-Weinberg proportions. Hardy-Weinberg Proportions Methods Manual Version 0.1.2. (2009).
32. Therneau T.M. & Grambsch P.M. Modeling Survival Data. Extending the Cox Model. Statistics for Biology and Health (Springer, New york, 2000).